Navigation Links
Arsenic Compound Effective in Treating Rare Leukemia

Through their participation in a national study, patients being treated for a rare form of leukemia by doctors at North Shore University Hospital// (NSUH) and Long Island Jewish (LIJ) Medical Center have helped confirm that an arsenic compound, coupled with standard chemotherapy treatments, significantly increases long-term survival.

Patients all had newly-diagnosed acute promyelocytic leukemia, or APL, and participated in a multi-year national phase III clinical study. Twenty eight patients from NSUH and LIJ enrolled in the clinical trials, the largest number of participants from any facility in the New York metropolitan area – and the second largest nationwide. The study involved 582 patients nationally over six years -- from June 1999 through March 2005. It was sponsored by the National Institutes of Health’s National Cancer Institute. The study findings were recently released prior to formal publication so that all APL patients could benefit sooner from the therapy, according to the NCI.

Jonathan Kolitz, MD, director of the leukemia service at NSUH’s Don Monti Division of Medical Oncology at the Monter Cancer Center in Lake Success, said the trial shows that APL is essentially curable in many patients, a term he doesn’t use lightly. “I believe arsenic trioxide will become part of the new standard protocol for treatment of APL in many patients,” he said.

Vicki Murphy, a 59-year-old resident of Oyster Bay, was diagnosed with APL in 2000. She was the first patient to enroll in the study at NSUH. After going through several rounds of chemotherapy to put her leukemia into remission, she said she went back to the hospital daily for nearly three months to receive the additional arsenic trioxide therapy. “I was scared but I also knew this trial was my chance for a cure,” she explained. “It’s always scary when you’re facing the unknown.”

In the randomized trials, patients with APL were given either several rounds of standar d chemotherapy drugs combined with the retinoid ATRA, a vitamin A derivative plus a post-remission regimen of additional chemotherapy and ATRA followed by a year of maintenance chemotherapy using oral agents, including ATRA, or the identical regimen plus two 25-day courses of arsenic trioxide prior to the post-remission therapy. Patients receiving the arsenic trioxide had significantly better likelihood of remaining disease-free and surviving than those receiving standard chemotherapy alone. Patients in remission also underwent an additional year of ATRA, with or without oral chemotherapy, to ensure they remained cancer-free.

“These patients endured additional months of therapy, with 25 days of two-hour infusions of arsenic given over five weeks,” explained Dr. Kolitz. “Then, after a short break, they had to do it all over again.” Study patients also underwent extensive follow-up, including weekly blood tests and regular bone marrow tests. They will be monitored for life.

Ms. Murphy said study participants got through the ordeal thanks to the support of each other and staff at NSUH and LIJ. “I wouldn’t be here, I wouldn’t have been able to endure the treatments if it wasn’t for their support and encouragement,” said Ms. Murphy, a grandmother, journalist, musician and activist. “The entire staff was incredibly supportive and provided lots of encouragement, especially during the times I wasn’t sure I could get through this,” she said.

In acute leukemia, the bone marrow doesn’t mature properly, and eventually crowds out normal cells. APL, a subtype of acute myeloid leukemia (AML), affects about 1,500 patients each year, about 10 percent of AML cases. It primarily strikes middle-aged adults. AML is an acquired, not genetic, condition, which helps to explain why previously healthy people can develop it. While scientists are still unsure of what causes AML, they believe long-term exposure to certain chemicals, such as benzene, may be a risk factor.

Ms. Murphy has been in remission for nearly seven years and says she owes more than she can ever fully express to Dr. Kolitz and his healthcare team. “I took it one day at a time, and although there were good days and bad days, the support I got meant I never completely lost hope,” she said. She is now looking forward to many long and productive years with her family, friends and colleagues.
br>Source-Newswise
SRM
'"/>




Related medicine news :

1. Chickens Found To Have High Levels of Arsenic
2. Arsenic poisoning reactions can be traced to genes
3. Arsenic May Have Been Responsible For The Madness Of King George III Of England
4. Arsenic in drinking water
5. Arsenic in Drinking Water Predisposes Children To Lung Cancer in Later Life
6. Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc
7. Arsenic in Chicken Feed may Cause Health Complications
8. Compound of Broccoli combats breast cancer
9. New Compound Could Strengthen The Effect Of Chemotherapy
10. Breathing Cancer Causing Compounds During Pregnancy Found To Affect Offspring
11. Compound from cottonseed for neck and head cancers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare ... audience, will be participating in Rare Disease Day events, hosted by the Rare ... Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. Hamid ... sponsoring a raffle. Throughout the month of February, patients who visit Hamlin Dental Group ... for a dinner for two at the Cheesecake Factory. , Tickets are available ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... “Doping in Sport: How the Culture Might Change,” in conjunction with ... symposium will be held at Pepperdine University in Malibu, California. , Sir Philip ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  Genesis Healthcare Services has ... announcement was made by Bill Monast , President ... and Nathan Feltman , executives with Home ... Services, LLC. This acquisition helps Hospice ... of technology enabled durable medical equipment (DME) solutions for ...
(Date:2/23/2017)... 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... proprietary products for the urology market, will release financial ... December 31, 2016 before the market open on Thursday, ... host a conference call and webcast to discuss its ... 2017 at 11:00 a.m. Eastern Time (10:00 a.m. Central ...
(Date:2/23/2017)... Calif., Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), ... solutions for the treatment of chronic pain, today reported financial ... 31, 2016. 2016 Accomplishment & Highlights: ... year 2016, an increase of 228% as reported, over the ... 2016, an increase of 612% over the prior year ...
Breaking Medicine Technology: